Skip to main content

Trio of Banks Initiate Coverage of GenMark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Three investment banks have initiated coverage of GenMark Diagnostics with favorable ratings.

Piper Jaffray issued an "overweight" rating and an $8 price target on GenMark's stock, saying its current valuation does not reflect the potential of the firm's technology or assay pipeline.

William Blair also initiated coverage with an "outperform" rating, and ThinkEquity initiated coverage with a "buy" rating.

GenMark was formerly known as Osmetech. The molecular diagnostics firm moved its headquarters to the US and began floating on the Nasdaq on the last day of May. Its US IPO was priced at $6 per share, but its stock has fallen since then.

In Monday afternoon trade, shares of GenMark were up 1 percent at $4.81.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.